Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 231

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 231
---
 normal recurring nature necessary for the fair presentation of the Company’s financial position as of June 30, 2025, as well
as its results of operations and cash flows for the six months ended June 30, 2025, and 2024. The results of operations for the six and
three months ended June 30, 2025, are not necessarily indicative of the results to be expected for the year ending December 31,
2025.

| NOTE 4: - | BASIC AND DILUTED LOSS PER SHARE : |

Basic
loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding
during the reporting period. Diluted loss per share is computed similarly to basic loss per share except that the weighted average number
of shares outstanding is increased to include additional shares from the assumed exercise of stock options and warrants, if dilutive.
The average number of shares is calculated by assuming that outstanding conversions were exercised and that the proceeds from such exercises
were used to acquire common shares at the average market price during the reporting period, potentially dilutive common shares issuable
upon the exercise of warrants and options were not included in the computation of loss per share because their effect was anti-dilutive.

The loss
and the weighted average number of shares used in computing basic and diluted net loss per share for the 3 months period ended March
31, 2025 and 2024, are as follows:

|                                                              |     |                Successor |            |     | Predecessor |         |     |                  Successor |            |     | Predecessor |         |
|                                                              |     | For the six months ended 
                 June 30, |            |     |             |         |     | For the three months ended 
                   June 30, |            |     |             |         |
|                                                              |     |                     2025 |            |     |        2024 |         |     |                       2025 |            |     |        2024 |         |
|                                                              |     |                Unaudited |            |     |   Unaudited |         |     |                  Unaudited |            |     |   Unaudited |         |
| Numerator:                                                   |     |                          |            |     |             |         |     |                            |            |     |             |         |
| Net loss applicable to shareholders of Ordinary              
 Share                                                        |     |                          |      1,606 |